Information about Deconib
My details
*
*
*

Company information

Status
Active

Enterprise number

BE0425.919.575

VAT liability
Yes
Established
21-12-1983
Last balance sheet year
2024
Company size
Medium-sized 1 FTE
Principal activity
Business and other management consultancy activities
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Deconib

2024 2023 2022 2021
Profit/Loss 202,738 18 % 171,100 443 % 31,491 168 % -46,549
Equity 3,007,382 7 % 2,804,645 -20 % 3,497,545 -19 % 4,330,054
Gross margin 1,150,667 11 % 1,038,777 3 % 1,008,623 -7 % 1,079,187
Employees 1 1 1 2.9

Publications from Deconib

Date Publication
19-04-2022 Resignations - Appointments (NL)
07-05-2021 Articles of Association (Translation, Coordination, Other Modifications, …) (NL)
22-04-2021 Resignations - Appointments (NL)
02-10-2017 Rubric Restructuring (Fusion, Split, Transfer of Assets, etc...) (NL)
24-05-2017 Rubric Restructuring (Fusion, Split, Transfer of Assets, etc...) (NL)

Frequently asked questions

What is the VAT number of Deconib?
The VAT number of Deconib is BE 0425.919.575.
Wat is the PEPPOL ID of Deconib?
The PEPPOL ID of Deconib is 0208:0425919575. Log in or start a free trial to see the full overview.
When was Deconib founded?
Deconib was founded on 21-12-1983.
What is the address of Deconib?
The current registered office of Deconib is located at Aalterbaan 119, 9990 Maldegem.
When was the last time Deconib filed their annual financial statements?
The most recent financial statements of Deconib were filed on 27-08-2025.
How many employees does Deconib have?
There are 1 FTEs working at Deconib according to the staff figures in the most recent financial statements.
What is the annual turnover of Deconib?
At the time of its most recent financial statements, Deconib did not publish any turnover figures. Deconib reported a gross margin of €1,150,667.00.